Comparison of effects of thrombolytic therapy on left ventricular function in patients over with those under 60 years of age
- PMID: 1902054
- DOI: 10.1016/0002-9149(91)90160-m
Comparison of effects of thrombolytic therapy on left ventricular function in patients over with those under 60 years of age
Abstract
This study examined the effect of age on left ventricular (LV) function, assessed by contrast ventriculography 3 weeks after a first acute myocardial infarction in 312 patients who received thrombolytic therapy within 4 hours of the onset of infarction and in 83 patients who received placebo. Streptokinase was given to 188 patients and recombinant tissue-type plasminogen activator (rt-PA) to 124. Patients were divided into 2 age groups: less than 60 years (n = 244) and greater than or equal to 60 years (n = 151). Thrombolytic therapy improved ejection fraction in both age groups: from 54 +/- 13 to 59 +/- 11% (p = 0.021) in the younger group and from 50 +/- 14 to 57 +/- 13% (p = 0.004) in the older group. Ejection fraction was identical in streptokinase- and rt-PA-treated patients. Multifactor analysis of variance revealed that younger age and thrombolytic therapy were independently associated with improved ejection fraction. Thrombolytic therapy also reduced end-systolic volume (p = 0.001) by 14 ml in the elderly and 9 ml in the younger group. Minor bleeding complications were more frequent in the elderly and 3 serious hemorrhages occurred in patients greater than or equal to 60 years. These findings reveal that thrombolysis improves LV function in all age groups studied. Because increasing age is independently associated with a lower ejection fraction after acute myocardial infarction, thrombolytic therapy may confer greater benefits in older patients.
Similar articles
-
A difference between front-loaded streptokinase and standard-dose recombinant tissue-type plasminogen activator in preserving left ventricular function after acute myocardial infarction (the Central Illinois Thrombolytic Therapy Study).Am J Cardiol. 1993 Nov 1;72(14):1010-4. doi: 10.1016/0002-9149(93)90854-6. Am J Cardiol. 1993. PMID: 8213579 Clinical Trial.
-
Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction.N Engl J Med. 1989 Mar 30;320(13):817-21. doi: 10.1056/NEJM198903303201301. N Engl J Med. 1989. PMID: 2494454 Clinical Trial.
-
Increased left ventricular dysfunction in elderly patients despite successful thrombolysis: the GUSTO-I angiographic experience.J Am Coll Cardiol. 1996 Aug;28(2):331-7. doi: 10.1016/0735-1097(96)00148-9. J Am Coll Cardiol. 1996. PMID: 8800106 Clinical Trial.
-
New developments in thrombolytic therapy.Adv Exp Med Biol. 1990;281:333-54. Adv Exp Med Biol. 1990. PMID: 2129372 Review.
-
[Acute myocardial infarction: immediate coronary angioplasty for failure or contra-indications of thrombolytic therapy. Apropos of a series of 100 cases].Arch Mal Coeur Vaiss. 1991 Apr;84(4):469-75. Arch Mal Coeur Vaiss. 1991. PMID: 1905914 Review. French.
Cited by
-
Does the potential for development of streptokinase antibodies change the risk-benefit ratio in older patients?Drugs Aging. 1995 Aug;7(2):110-6. doi: 10.2165/00002512-199507020-00005. Drugs Aging. 1995. PMID: 7579782 Review.
-
Optimising thrombolytic therapy in elderly patients with acute myocardial infarction.Drugs Aging. 1996 Jan;8(1):17-22. doi: 10.2165/00002512-199608010-00004. Drugs Aging. 1996. PMID: 8785464 Review.
-
Streptokinase. A review of its pharmacology and therapeutic efficacy in acute myocardial infarction in older patients.Drugs Aging. 1994 Jan;4(1):63-86. doi: 10.2165/00002512-199404010-00007. Drugs Aging. 1994. PMID: 8130384 Review.
-
Pharmacoeconomic aspects of treatment of acute myocardial infarction with thrombolytic agents.Pharmacoeconomics. 1993 Mar;3(3):192-204. doi: 10.2165/00019053-199303030-00003. Pharmacoeconomics. 1993. PMID: 10172049 Review.
-
Comparative tolerability profiles of thrombolytic agents. A review.Drug Saf. 1993 Jan;8(1):19-29. doi: 10.2165/00002018-199308010-00004. Drug Saf. 1993. PMID: 8471185 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical